Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

IDbyDNA Expands Scientific Advisory Board with Infectious Disease, Sequencing & FDA Leaders

Innovator in Precision Metagenomics Adds Experts in Regulatory Compliance, Clinical Medicine, and Pathology to Drive Next Phase of Growth


News provided by

IDbyDNA

Oct 13, 2021, 13:00 ET

Share this article

Share toX

Share this article

Share toX


SAN FRANCISCO, Oct. 13, 2021 /PRNewswire-PRWeb/ -- On the heels of its appointment of Next-Generation Sequencing (NGS) leader Neil Gunn as CEO, IDbyDNA is announcing the additions of several notable leaders to their Scientific Advisory Board, including Dr. Adrian Egli, Head of Clinical Bacteriology and Mycology at the University Hospital in Basel, Switzerland and Dr. Tamara V. Feldblyum, who most recently served at the Food and Drug Administration (FDA). Egli and Feldblyum are joined by Dr. Karl Voelkerding, one of the world's leading experts in next-generation sequencing; Dr. Christopher Woods, Executive Director of the Hubert-Yeargan Center for Global Health and professor of Medicine and Pathology at Duke University; and Dr. Stephen Young, Director of Research and Clinical Trials at TriCore Reference Laboratory.

The COVID-19 pandemic has reinforced the need and use case for metagenomics to help support complex clinical cases, including the detection and characterization of SARS-CoV-2 and implications of co-infections. By providing deeper insights into the complete pathogen profile, Precision Metagenomics is capable of delivering comprehensive data to better inform treatment of critically-ill patients. IDbyDNA and its growing team are well positioned to broaden the availability of its platform for rapid identification and actionable insights needed to better understand and classify infectious diseases.

The promise and power of IDbyDNA’s approach to democratizing Precision Metagenomics has never been more evident, and we are delighted to welcome these esteemed leaders to our Scientific Advisory Board.

Post this

"The promise and power of IDbyDNA's approach to democratizing Precision Metagenomics has never been more evident, and we are delighted to welcome these esteemed leaders to our Scientific Advisory Board" said Gunn. "These additions reinforce our commitment to bringing together the best and brightest in the field to make our mission a reality - and we recognize the impact of having Adrian, Tamara, Karl, Christopher, and Steve join our team - particularly as it relates to our progress in the regulatory, diagnostic and antimicrobial resistance space. We know this is just the beginning of a very significant period in our evolution as a company and reinforces our role as the leader in precision metagenomics."

More about IDbyDNA's new advisory board members:

  • Dr. Adrian Egli: Is the head of Clinical Bacteriology and Mycology at the University Hospital Basel and an Independent Research Group Leader at the Department of Biomedicine, University of Basel. As a physician scientist, he has pioneered the introduction of whole genome sequencing, metagenomics, transcriptomics, and artificial intelligence in clinical microbiology.
  • Dr. Tamara Feldblyum: Served for 15 years at the FDA's CDRH's Office of In Vitro Diagnostics and Radiological Health as a Branch Chief in the Division of Microbiology Devices and was also the director of a core sequencing facility at The Institute for Genomic Research, where she was responsible for genome library construction, high throughput sequencing, genome finishing, quality control and assurance, research and development, new technology implementation, and more.
  • Dr. Karl Voelkerding: Dr. Karl Voelkerding is one of the world's leading experts in diagnostic genomics. As part of the College of American Pathologists and the Association for Molecular Pathology he has led the development of guidelines and recommendations for best practices in NGS-based testing.
  • Dr. Christopher Woods: Serves as Chief of Infectious Diseases for the Durham VA Medical Center. He has published over 210 peer-reviewed articles. His genomic approach to harnessing the host response for diagnosis of infectious diseases has been called a paradigm shift in the field.
  • Dr. Stephen Young: Steve Young is an infectious disease pioneer. During his decades-long career, Dr. Young has provided technical expertise and laboratory operations experience to approximately 40 in-vitro diagnostics device companies and has completed over 200 FDA clinical trials, contributing immeasurable breadth of clinical understanding in the field of microbiological diagnostics.

"This is a pivotal time for the global health community - and with it, the world has become keenly aware of the potential sequencing may have in expanding our knowledge about infectious diseases," added Feldblyum. "Having spent more than a decade at the FDA, I look forward to helping IDbyDNA accelerate the availability of its platform so that clinicians and researchers can take advantage of metagenomics."

About IDbyDNA
IDbyDNA is driving a paradigm shift in infectious disease testing by democratizing the power of Precision Metagenomics, delivering precise insights for better health. Explify®* data analytics enable laboratories to detect and profile microorganisms from any specimen in a scalable, intuitive way at genomic-level resolution. Our industry-leading expertise in microbial genomics delivers complete infection profiles for infectious disease testing and pathogen surveillance. For more information, visit http://www.idbydna.com.

*For Research Use Only. Not for use in diagnostic procedures.

Media Contact

Aimee Eichelberger, Superior PR, 3129521528, [email protected]

SOURCE IDbyDNA

Related Links

http://www.idbydna.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.